Abstract
Recent findings in a clinical trial in which an adeno-associated virus (AAV) vector expressing coagulation factor IX (F.IX) was introduced into the liver of hemophilia B subjects highlighted a new issue previously not identified in animal studies. Upon AAV gene transfer to liver, two subjects enrolled in this trial developed transient elevation of liver enzymes, likely as a consequence of immune rejection of transduced hepatocytes mediated by AAV capsid-specific CD8+ T cells. Studies in healthy donors showed that humans carry a population of antigen-specific memory CD8+ T cells probably arising from wild-type AAV infections. The hypothesis formulated here is that these cells expanded upon re-exposure to capsid, i.e. upon AAV-2 hepatic gene transfer, and cleared AAV epitope-bearing transduced hepatocytes. Other hypotheses have been formulated which include specific receptor-binding properties of AAV-2 capsid, presence of capsidexpressing DNA in AAV vector preparations, and expression of alternative reading frames from the transgene. Absence of a valid animal model has prevented an in-depth mechanistic study of the phenomenon. Several possible solutions to the problem are discussed, including the administration of a short-term anti-T cell immunosuppression regimen concomitant with gene transfer. While more studies will be necessary to further define mechanisms and risks associated with capsidspecific immune responses in humans, monitoring of these responses in clinical trials will be essential to achieving the goal of long-term therapeutic gene transfer in humans.
Keywords: Adeno-associated virus, AAV, immune response, gene therapy, clinical trial, CD8 T cells, capsid, liver
Current Gene Therapy
Title: Immune Responses to AAV in Clinical Trials
Volume: 7 Issue: 5
Author(s): Federico Mingozzi and Katherine A. High
Affiliation:
Keywords: Adeno-associated virus, AAV, immune response, gene therapy, clinical trial, CD8 T cells, capsid, liver
Abstract: Recent findings in a clinical trial in which an adeno-associated virus (AAV) vector expressing coagulation factor IX (F.IX) was introduced into the liver of hemophilia B subjects highlighted a new issue previously not identified in animal studies. Upon AAV gene transfer to liver, two subjects enrolled in this trial developed transient elevation of liver enzymes, likely as a consequence of immune rejection of transduced hepatocytes mediated by AAV capsid-specific CD8+ T cells. Studies in healthy donors showed that humans carry a population of antigen-specific memory CD8+ T cells probably arising from wild-type AAV infections. The hypothesis formulated here is that these cells expanded upon re-exposure to capsid, i.e. upon AAV-2 hepatic gene transfer, and cleared AAV epitope-bearing transduced hepatocytes. Other hypotheses have been formulated which include specific receptor-binding properties of AAV-2 capsid, presence of capsidexpressing DNA in AAV vector preparations, and expression of alternative reading frames from the transgene. Absence of a valid animal model has prevented an in-depth mechanistic study of the phenomenon. Several possible solutions to the problem are discussed, including the administration of a short-term anti-T cell immunosuppression regimen concomitant with gene transfer. While more studies will be necessary to further define mechanisms and risks associated with capsidspecific immune responses in humans, monitoring of these responses in clinical trials will be essential to achieving the goal of long-term therapeutic gene transfer in humans.
Export Options
About this article
Cite this article as:
Mingozzi Federico and High A. Katherine, Immune Responses to AAV in Clinical Trials, Current Gene Therapy 2007; 7 (5) . https://dx.doi.org/10.2174/156652307782151425
DOI https://dx.doi.org/10.2174/156652307782151425 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Development of High-throughput Identification and Heterologous Expression of Valuable Peptides/Proteins
Current Proteomics Predicting Inhibitors for Multidrug Resistance Associated Protein-2 Transporter by Machine Learning Approach
Combinatorial Chemistry & High Throughput Screening Modifications of the Immune Responsiveness in Patients with Autoimmune Thyroiditis: Evidence for a Systemic Immune Alteration
Current Pharmaceutical Design Metabolic Effects of Bile Acids in the Gut in Health and Disease
Current Medicinal Chemistry Hepatic Cytochrome P450 Regulation in Disease States
Current Drug Metabolism Lysosomal Storage Diseases and the Blood-Brain Barrier
Current Pharmaceutical Design Autophagy and Mitochondria in Obesity and Type 2 Diabetes
Current Diabetes Reviews Supramolecular Nanomedicine - An Overview
Current Drug Targets Cellomics as Integrative Omics for Cancer
Current Proteomics Rational Basis for the Use of Bergamot Essential Oil in Complementary Medicine to Treat Chronic Pain
Mini-Reviews in Medicinal Chemistry Anesthesia for Bronchoscopy
Current Pharmaceutical Design Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Role of Wnt Signaling in the Control of Adult Hippocampal Functioning in Health and Disease: Therapeutic Implications
Current Neuropharmacology Nanotechnology approaches for pain therapy through transdermal drug delivery
Current Pharmaceutical Design Current Status of Newer Carbapenems
Current Medicinal Chemistry Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology The Relationship of Mother's Spiritual Well-being and Forgiveness with Mother-to-infant Attachment in Women Referring to Maternity Hospital Affiliated to Shiraz University of Medical Sciences
Current Women`s Health Reviews Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential
Current Medicinal Chemistry Liver Transporters in Hepatic Drug Disposition: An Update
Current Drug Metabolism